Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects

[1]  C. Curtis,et al.  Quantitative evidence for early metastatic seeding in colorectal cancer , 2019, Nature Genetics.

[2]  M. Esteller,et al.  SIPA1L3 methylation modifies the benefit of smoking cessation on lung adenocarcinoma survival: an epigenomic–smoking interaction analysis , 2019, Molecular oncology.

[3]  M. Esteller,et al.  EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC , 2019, Epigenetics.

[4]  Guang-Biao Zhou,et al.  Genome-wide identification of transcription factors that are critical to non-small cell lung cancer. , 2018, Cancer letters.

[5]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[6]  M. Esteller,et al.  DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Non–Small Cell Lung Cancer Patients , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[7]  M. Esteller,et al.  A multi‐omic study reveals BTG2 as a reliable prognostic marker for early‐stage non‐small cell lung cancer , 2018, Molecular oncology.

[8]  Xihong Lin,et al.  Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC , 2018, Clinical Epigenetics.

[9]  Yang Feng,et al.  SIS: An R Package for Sure Independence Screening in Ultrahigh-Dimensional Statistical Models , 2018 .

[10]  Jack Cuzick,et al.  Use of the concordance index for predictors of censored survival data , 2016, Statistical methods in medical research.

[11]  N. Lindeman,et al.  The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. , 2017, Blood.

[12]  Walter J Curran,et al.  Lung cancer: current therapies and new targeted treatments , 2017, The Lancet.

[13]  Lin Zhang,et al.  Cancer Progression Prediction Using Gene Interaction Regularized Elastic Net. , 2017, IEEE/ACM transactions on computational biology and bioinformatics.

[14]  Hui Liu,et al.  Cancer Progression Prediction Using Gene Interaction Regularized Elastic Net , 2017, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[15]  Claude Preudhomme,et al.  A 17-gene stemness score for rapid determination of risk in acute leukaemia , 2016, Nature.

[16]  Dejia Li,et al.  MicroRNA-187-3p mitigates non-small cell lung cancer (NSCLC) development through down-regulation of BCL6. , 2016, Biochemical and biophysical research communications.

[17]  Vessela Kristensen,et al.  Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis , 2015, Molecular oncology.

[18]  Haixiu Yang,et al.  A potential signature of eight long non-coding RNAs predicts survival in patients with non-small cell lung cancer , 2015, Journal of Translational Medicine.

[19]  Qing Zhao,et al.  Combining multidimensional genomic measurements for predicting cancer prognosis: observations from TCGA , 2015, Briefings Bioinform..

[20]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[21]  Yi Wang,et al.  Genome-wide Association Study of Survival in Early-stage Non-Small Cell Lung Cancer , 2015, Annals of Surgical Oncology.

[22]  Johan Staaf,et al.  Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome , 2014, Clinical Cancer Research.

[23]  K. Kiura,et al.  The Role of STAT3 in Non-Small Cell Lung Cancer , 2014, Cancers.

[24]  M. Esteller,et al.  A prognostic DNA methylation signature for stage I non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[26]  J. Tegnér,et al.  An evaluation of analysis pipelines for DNA methylation profiling using the Illumina HumanMethylation450 BeadChip platform , 2013, Epigenetics.

[27]  I. Wistuba,et al.  RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. , 2013, Cancer discovery.

[28]  R. Weksberg,et al.  Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray , 2013, Epigenetics.

[29]  Huijun Zhu,et al.  High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. , 2012, American journal of clinical pathology.

[30]  Peter Kraft,et al.  Inclusion of gene-gene and gene-environment interactions unlikely to dramatically improve risk prediction for complex diseases. , 2012, American journal of human genetics.

[31]  Bjarni J. Vilhjálmsson,et al.  An efficient multi-locus mixed model approach for genome-wide association studies in structured populations , 2012, Nature Genetics.

[32]  H. Izumi,et al.  NDRG1/Cap43/Drg-1 may Predict Tumor Angiogenesis and Poor Outcome in Patients with Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  C. Kingsley,et al.  STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma , 2012, PloS one.

[34]  Lei-na Sun,et al.  Correlation of Activated STAT3 Expression with Clinicopathologic Features in Lung Adenocarcinoma and Squamous Cell Carcinoma , 2011, Molecular Diagnosis & Therapy.

[35]  Fang Zhou,et al.  A 5-MicroRNA Signature for Lung Squamous Cell Carcinoma Diagnosis and hsa-miR-31 for Prognosis , 2011, Clinical Cancer Research.

[36]  Judy H Cho,et al.  Improved risk prediction for Crohn's disease with a multi-locus approach. , 2011, Human molecular genetics.

[37]  Gary D. Bader,et al.  The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function , 2010, Nucleic Acids Res..

[38]  H. Cordell.  Detecting gene–gene interactions that underlie human diseases , 2009, Nature Reviews Genetics.

[39]  E. Wardelmann,et al.  Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling , 2009, Journal of Cancer Research and Clinical Oncology.

[40]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[41]  B. Ponder,et al.  Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.

[42]  Y. Yatabe,et al.  Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer , 2007, Cancer science.

[43]  I. Roninson,et al.  The STAT3 oncogene as a predictive marker of drug resistance. , 2007, Trends in molecular medicine.

[44]  E. Shimizu,et al.  Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells. , 2005, Oncology reports.

[45]  Peter A. Jones,et al.  Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.

[46]  S. Vicent,et al.  ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours , 2004, British Journal of Cancer.

[47]  A. Feinberg,et al.  The history of cancer epigenetics , 2004, Nature Reviews Cancer.

[48]  M. Khoury,et al.  An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions , 2004, Genetics in Medicine.

[49]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.